mesalamine and pulmicort

mesalamine has been researched along with pulmicort in 134 studies

Research

Studies (134)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's16 (11.94)18.2507
2000's42 (31.34)29.6817
2010's66 (49.25)24.3611
2020's10 (7.46)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Andus, T; Gross, V; Schölmerich, J1
Irvine, EJ; Marshall, JK1
Ekström, GM1
Rutgeerts, P; Vermeire, S1
Tytgat, GN; van Deventer, SJ1
Breslin, NP; Sutherland, LR1
Cortot, A; Jewell, D; Persson, T; Pettersson, E; Thomsen, OO; Vatn, M; Veloso, FT; Winter, T; Wright, JP2
Bickston, SJ; Cominelli, F1
Klotz, U1
Stange, EF2
Lowry, PW; Sandborn, WJ1
Hüppe, D; Schenck, B; Tromm, A1
Rutgeerts, P1
Hellström, PM; Ljung, T; Martinsson, T; Rubio, C1
Takada, K1
Frühmorgen, P; Huber, W; Kimmig, JM; Rufle, W1
Rachmilewitz, D1
de Groot, H; de Man, RA; Heeringa, M; Zweers, P1
Sutherland, LR1
Fleig, WE2
Evans, DF; Kumar, D; Nugent, SG; Rampton, DS1
Rutgeerts, PJ1
Adler, G; König, HH; Leidl, R; Reinshagen, M; Rösch, M; Thomas, S; von Tirpitz, C1
Farthing, MJ1
Niemelä, S1
Feagan, BG; Hofer, T; Kane, SV; Sandborn, WJ; Schoenfeld, P; Tremaine, W1
Cohen, RD1
Feagan, BG; Sandborn, WJ2
Castro Fernández, M; Galán Jurado, V; García Díaz, E; Rodríguez Alonso, C; Romero, M1
Schölmerich, J1
Espinós, J; Esteve, M; Fernández-Bañares, F; Forné, M; Salas, A; Viver, JM1
Kullak-Ublick, GA; Rammert, Ch1
Beglinger, Ch1
Calabrese, E; Cammà, C; Casà, A; Cottone, M; Orlando, A; Viscido, A1
Archavlis, E; Chadio-Iordanides, H; Christidou, A; Mantzaris, GJ; Petraki, K; Sfakianakis, M; Triadaphyllou, G1
Dressman, J; Klein, S; Stein, J1
Munck, LK1
Büning, C; Lochs, H1
Gottesleben, F1
Lakatos, L; Lakatos, PL1
Thomson, A1
de Castro Losa, MR; de la Iglesia Fanjul, I; Izquierdo García, F1
Detsky, A; Kennedy, ED; Llewellyn-Thomas, HA; McLeod, RS; Steinhart, AH; To, T1
Chande, N; Macdonald, JK; McDonald, JW2
Bakulin, IG; Stanke, DA1
Bell, AJ; Ciclitira, PJ; Clark, SK; McLaughlin, SD; Nicholls, RJ; Tekkis, PP1
Bischoff, A1
Ahmadi, F; Dorkoosh, F; Emami, J; Fassihi, A; Mahzouni, P; Minaiyan, M; Tavakoli, N; Varshosaz, J1
Hartmann, F; Stein, J1
Bourke, B; Cortelazzo, S; Piccin, A; Rovigatti, U; Smith, OP1
Dennis, M; Jamma, S; Kelly, CP; Leffler, DA; Najarian, RM; Schuppan, DB; Sheth, S1
Griffiths, AM; Seow, CH; Sherlock, ME; Steinhart, AH1
Altorjay, I; Bar-Meir, S; Bátovský, M; Bunganič, I; Dilger, K; Fixa, B; Gabalec, L; Glasmacher, C; Greinwald, R; Koutroubakis, I; Kramm, HJ; Kykal, J; Löhr, H; Lukáš, M; Mohrbacher, R; Safadi, R; Schäffeler, E; Stimac, D; Tomsová, E; Tromm, A; Tulassay, Z1
Hanauer, S; Lim, WC1
Belousova, EA; Bunganic, I; Derova, J; Dilger, K; Dorofeyev, AE; Gabalec, L; Greinwald, R; Gross, V; Kiudelis, G; Kupcinskas, L; Mikhailova, TL; Mueller, R; Tulassay, Z1
Blumenstein, I; Bock, H; Dignass, A; Filmann, N; Hartmann, F; Herrmann, E; Schröder, O; Stein, J; Tacke, W; Zeuzem, S; Zosel, C1
Blonski, W; Buchner, AM; Lichtenstein, GR1
Danese, S; Fiorino, G; Montorsi, M; Sacchi, M; Spinelli, A1
Bousvaros, A; Carvalho, R; Evans, J; Griffiths, A; Grossman, A; Hyams, J; Kay, M; Keljo, D; Langton, C; LeLeiko, N; Lerer, T; Mack, D; Markowitz, J; Oliva-Hemker, M; Otley, A; Pfefferkorn, M; Rosh, J; Samson, C; Stephens, M1
Cheon, JH; Choi, CH; Jang, BI; Kim, YH; Lee, H; Lee, KM; Shin, SJ; Yang, SK; Ye, BD1
Ascolani, M; Biancone, L; Boirivant, M; Cossu, A; Pallone, F1
Bagin, R; Ballard, ED; Gautille, T; Huang, M; Jones, R; Moro, L; Sandborn, WJ; Travis, S; Yeung, P1
Wenzl, HH1
Biedermann, L; Frei, P; Manser, CN; Manz, M; Rogler, G; Vavricka, SR; Wilk, M1
Gross, V1
Erichsen, Jv; Hessmann, M; Hoffmeyer, A; Pahl, A; Sann, H1
D'Haens, GR; Rietdijk, ST1
Beglinger, C; Fournier, N; Mottet, C; Pittet, V; Rogler, G; Seibold, F1
Aratari, A; Clemente, V; De Gregorio, AM; Fascì Spurio, F; Koch, M; Margagnoni, G; Papi, C; Spagnolo, A1
Bach, H; Bressler, B; Grist, J; Silverberg, MS; Stempak, JM; Xia, A1
Böhm, G; Bonderup, OK; Fernández-Bañares, F; Greinwald, R; Kupcinskas, L; Madisch, A; Marks, HJ; Miehlke, S; Mohrbacher, R; Nathan, T; Neumeyer, M; Petrauskas, D; Vieth, M1
Rogler, G; Scharl, M; Schoepfer, AM; Vavricka, SR1
Danese, S; Peyrin-Biroulet, L; Siegel, CA1
Antoniu, SA; Drug, VL1
Bagin, R; D'Haens, G; Danese, S; David Ballard, E; Huang, M; Jones, R; Masure, J; Moro, L; Sandborn, WJ; Travis, S1
Bonovas, S; Danese, S; Del Giovane, C; Fiorino, G; Moja, L1
Benchimol, EI; Griffiths, AM; Kaplan, GG; Kuenzig, ME; Otley, AR; Rezaie, A; Seow, CH; Steinhart, AH1
Geboes, K; Jauregui-Amezaga, A; Vermeire, S1
Griffiths, AM; MacDonald, JK; Seow, CH; Sherlock, ME; Steinhart, AH1
Chande, N; Feagan, BG; Marshall, JK; Nelson, S; Parker, CE; Sandborn, WJ; Seow, CH1
Bohr, J; Bonderup, OK; Greinwald, R; Madisch, A; Miehlke, S; Mohrbacher, R; Mueller, R; Münch, A; Ström, M; Tysk, C1
Stiefelhagen, P1
Eissens, AC; Frijlink, HW; Gareb, B; Kosterink, JGW1
Abdalla, MI; Herfarth, H1
Hanauer, S; Lim, WC; MacDonald, JK; Wang, Y1
Bosworth, BP; Harper, JR; Rubin, DT; Sandborn, WJ1
Andrade, P; Gomes, S; Macedo, G; Nunes, AC; Silva, M1
Bezzio, C; Fascì-Spurio, F; Meucci, G; Papi, C; Saibeni, S; Viganò, C1
Pardi, DS1
Im, JP; Kim, JW; Lee, H; Lee, KM; Park, DI; Park, JJ; Yang, SK; Ye, BD; Yoon, H; Yoon, SN1
Clement, F; Coward, S; Ghosh, S; Hazlewood, G; Holmes, R; Kaplan, GG; Kuenzig, ME; McBrien, K; Panaccione, R; Rezaie, A; Seow, CH1
Bonovas, S; Danese, S; Peyrin-Biroulet, L2
Axler, J; Barrett, AC; Bortey, E; Cohen, RD; Forbes, WP; Lichtenstein, GR; Riddell, RH; Rubin, DT; Sandborn, WJ; Zhu, C1
Al Yatama, N; Bhanji, T; Chande, N; MacDonald, JK; McDonald, JW; Nguyen, TM1
Chande, N; Kafil, TS; MacDonald, JK; McDonald, JW; Nguyen, TM; Patton, PH1
Bezzio, C; Festa, S; Manes, G; Papi, C; Saibeni, S; Zerboni, G1
Abdulkhakov, S; Alekseeva, O; Andreev, P; Datsenko, O; Dorofeyev, AE; Greinwald, R; Kruis, W; Levchenko, O; Lozynskyy, Y; Mohrbacher, R; Mostovoy, Y; Neshta, V; Pesegova, M; Siegmund, B; Soloviev, K; Stiess, M; Vieth, M1
Dulai, PS; Fumery, M; Murad, MH; Nguyen, NH; Prokop, LJ; Sandborn, WJ; Singh, S1
Armerding, P; Aust, D; Böhm, G; Bonderup, O; Fernández-Bañares, F; Greinwald, R; Kupcinskas, J; Miehlke, S; Mihaly, E; Münch, A; Munck, LK; Nacak, T; Rehbehn, KU1
Barańska-Rybak, W; Mehrholz, D; Nowak, M; Nowicki, J1
Ananthakrishnan, AN; Long, MD; Rubin, DT; Sauer, BG; Siegel, CA1
Afif, W; Bernstein, CN; Bitton, A; Borgaonkar, M; Bressler, B; Chauhan, U; Halloran, B; Jones, J; Kennedy, E; Khanna, R; Leontiadis, GI; Loftus, EV; Marshall, JK; Meddings, J; Moayyedi, P; Murthy, S; Panaccione, R; Plamondon, S; Rosenfeld, G; Schwartz, D; Seow, CH; Steinhart, AH; Targownik, L; Williams, C1
Kang, SB; Lee, J; Park, M; Park, Y1
Bonovas, S; Danese, S; González-Lorenzo, M; Lytras, T; Nikolopoulos, GK; Pantavou, K; Peyrin-Biroulet, L; Piovani, D1
Ardizzone, S; Bezzio, C; Bosani, M; Carmagnola, S; Cassinotti, A; Chibbar, R; Dell'Era, A; Grillo, S; Landi, S; Maconi, G; Massari, A; Mezzina, N; Molteni, P; Pastorelli, L1
Bonovas, S; D'Haens, G; Danese, S; Dignass, A; Dotan, I; Fiorino, G; Hart, A; Louis, E; Paridaens, K; Peyrin-Biroulet, L; Rogler, G1
Casanova, MJ; Gisbert, JP; Rojo, E1
Brandimarte, G; Cassieri, C; Colucci, R; Elisei, W; Picchio, M; Tursi, A1
Armentano, R; Cavalcanti, E; Lolli, I1
Derova, J; Fellermann, K; Greinwald, R; Jonaitis, L; Nacak, T; Rácz, I; Schiefke, I; Wehrum, S1
Kaliaperumal, S; Sahoo, NK; Senthamizh, T; Senthamizhselvan, K1
Atmakuri, S; Hoque, S; Khatri, D; Kumar, R; Madan, J; Mahajan, S; Maji, I; Modani, S; Singh, PK; Sriram, A; Srivastava, S; Tangirala, S1
Abdulkhakov, S; Abrahamovych, O; Alexeeva, O; Andreev, P; Baluta, M; Datsenko, O; Delmans, G; Dorofeyev, A; Greinwald, R; Kharchenko, N; Khimion, L; Kolesnik, IP; Kruis, W; Lesniakowski, K; Levchenko, O; Maksyashina, SV; Mihaly, E; Mohrbacher, R; Mostovoy, Y; Mueller, R; Pokrotnieks, J; Sablin, OA; Siegmund, B; Simanenkov, V; Sobon, M; Uspenskiy, Y; Viacheslav, N; Vieth, M1
Akita, Y; Iwashita, Y; Maruyama, Y; Miyashita, H; Miyazaki, R; Sakurai, T; Saruta, M; Shibuya, N; Shimada, M1
Caron, B; D'Amico, F; Danese, S; Jairath, V; Magro, F; Paridaens, K; Peyrin-Biroulet, L1
Aruljothy, A; Caron, B; Danese, S; Hogan, M; Jairath, V; Ma, C; MacDonald, JK; Moran, GW; Narula, N; Peyrin Biroulet, L; Singh, S; Vuyyuru, SK; Zayadi, A1

Reviews

60 review(s) available for mesalamine and pulmicort

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Crohn disease: prevention and drug therapy].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1995, Volume: 66, Issue:8

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Immunosuppressive Agents; Mesalamine; Pregnenediones; Recurrence

1995
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.
    Gut, 1997, Volume: 40, Issue:6

    Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Glucocorticoids; Humans; Mesalamine; Pregnenediones; Randomized Controlled Trials as Topic; Suppositories

1997
[Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection].
    Zentralblatt fur Chirurgie, 1998, Volume: 123, Issue:4

    Topics: Anti-Inflammatory Agents; Budesonide; Colon; Crohn Disease; Follow-Up Studies; Humans; Ileum; Mesalamine; Metronidazole; Postoperative Complications; Recurrence

1998
[Drug treatment of Crohn's disease].
    Nederlands tijdschrift voor geneeskunde, 1998, May-23, Volume: 142, Issue:21

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Clinical Protocols; Crohn Disease; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Mesalamine; Methotrexate; Prednisone; Remission Induction; Treatment Outcome

1998
The case against routine post-operative therapy for prevention of recurrence in Crohn's disease.
    Italian journal of gastroenterology and hepatology, 1998, Volume: 30, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Digestive System Surgical Procedures; Humans; Mesalamine; Metronidazole; Postoperative Period; Prognosis; Randomized Controlled Trials as Topic; Secondary Prevention

1998
[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
    Medizinische Klinik (Munich, Germany : 1983), 1999, Feb-15, Volume: 94 Suppl 1

    Topics: Budesonide; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Mesalamine; Structure-Activity Relationship

1999
[Consequences of galenic differences and outcome of clinical trials with budesonide and 5-aminosalicylic acids for therapy of Crohn disease].
    Medizinische Klinik (Munich, Germany : 1983), 1999, Feb-15, Volume: 94 Suppl 1

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Clinical Trials as Topic; Crohn Disease; Drug Delivery Systems; Humans; Mesalamine; Treatment Outcome

1999
[DDS preparations of drugs for inflammatory bowel disease].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:11

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Capsules; Delayed-Action Preparations; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Mesalamine; Prednisolone; Prodrugs

1999
[New therapeutic modalities in Crohn's disease].
    Harefuah, 1999, Jun-15, Volume: 136, Issue:12

    Topics: Anti-Inflammatory Agents; Budesonide; Crohn Disease; Humans; Mesalamine; Prednisolone

1999
Prevention of relapse of Crohn's disease.
    Inflammatory bowel diseases, 2000, Volume: 6, Issue:4

    Topics: Budesonide; Crohn Disease; Gastrointestinal Agents; Humans; Mesalamine; Secondary Prevention

2000
[Guidelines of the DGVS. Acute process. German Society of Digestive and Metabolic Diseases].
    Zeitschrift fur Gastroenterologie, 2001, Volume: 39, Issue:1

    Topics: Acute Disease; Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Drug Therapy, Combination; Humans; Mesalamine; Recurrence

2001
Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
    Gut, 2001, Volume: 48, Issue:4

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biological Availability; Budesonide; Catheterization; Electrodes; Humans; Hydrogen-Ion Concentration; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesalamine; Reference Values; Telemetry

2001
Conventional treatment of Crohn's disease: objectives and outcomes.
    Inflammatory bowel diseases, 2001, Volume: 7 Suppl 1

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Clinical Trials as Topic; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Mesalamine; Methotrexate; Prednisone; Quality of Life; Recurrence; Sulfasalazine; Treatment Outcome

2001
[Drug therapy of Crohn disease].
    Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:8

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Crohn Disease; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Secondary Prevention; Treatment Outcome

2001
The effectiveness of budesonide therapy for Crohn's disease.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:8

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Glucocorticoids; Humans; Mesalamine; Randomized Controlled Trials as Topic; Remission Induction

2002
Evolving medical therapies for ulcerative colitis.
    Current gastroenterology reports, 2002, Volume: 4, Issue:6

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antineoplastic Agents; Budesonide; Colitis, Ulcerative; Cyclosporine; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Interferons; Mesalamine; Treatment Outcome

2002
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Reviews in gastroenterological disorders, 2002, Volume: 2 Suppl 2

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Mesalamine; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome

2002
[Management of ulcerative colitis].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:3

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anemia; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antiviral Agents; Azathioprine; Budesonide; Clinical Trials as Topic; Colectomy; Colitis, Ulcerative; Colonic Pouches; Colonoscopy; Colorectal Neoplasms; Cyclosporins; Gastrointestinal Agents; Humans; Hydrocortisone; Immunosuppressive Agents; Infliximab; Injections, Intravenous; Interferons; Mercaptopurine; Mesalamine; Osteoporosis; Placebos; Practice Guidelines as Topic; Recurrence; Remission Induction; Risk Factors; Suppositories; Time Factors

2003
[Treatment of Crohn's disease].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:3

    Topics: Acute Disease; Adjuvants, Immunologic; Adrenal Cortex Hormones; Algorithms; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Case-Control Studies; Clinical Trials as Topic; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Metronidazole; Osteoporosis; Prednisolone; Prednisone; Randomized Controlled Trials as Topic; Time Factors

2003
Review article: prevention of postsurgical relapse and recurrence in Crohn's disease.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17 Suppl 2

    Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Immunosuppressive Agents; Mesalamine; Metronidazole; Ornidazole; Probiotics; Risk Factors; Secondary Prevention; Smoking

2003
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Alimentary pharmacology & therapeutics, 2003, Aug-01, Volume: 18, Issue:3

    Topics: Administration, Topical; Algorithms; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Controlled Clinical Trials as Topic; Crohn Disease; Gastrointestinal Agents; Glucocorticoids; Humans; Mesalamine; Sulfasalazine

2003
Conventional therapy for Crohn's disease.
    World journal of gastroenterology, 2006, Aug-14, Volume: 12, Issue:30

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Crohn Disease; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Nutrition Therapy; Randomized Controlled Trials as Topic; Remission Induction

2006
[Medical therapy of inflammatory bowel diseases: Crohn's disease].
    Orvosi hetilap, 2007, Jun-17, Volume: 148, Issue:24

    Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Chronic Disease; Crohn Disease; Fistula; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Mesalamine; Methotrexate; Severity of Illness Index

2007
Interventions for treating lymphocytic colitis.
    The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2

    Topics: Antidiarrheals; Bismuth; Budesonide; Cholestyramine Resin; Colitis, Lymphocytic; Humans; Mesalamine; Organometallic Compounds; Randomized Controlled Trials as Topic; Salicylates

2008
Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:1

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Cholestyramine Resin; Colitis, Microscopic; Humans; Mesalamine; Probiotics; Randomized Controlled Trials as Topic; Salicylates

2009
[Contemporary views on non-specific ulcerative colitis and conservative methods of its treatment ].
    Voenno-meditsinskii zhurnal, 2008, Volume: 329, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Budesonide; Colitis, Ulcerative; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Prednisolone

2008
[For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschritte der Medizin, 2009, May-07, Volume: 151, Issue:19

    Topics: Adolescent; Adult; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Child; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; Enteral Nutrition; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Mesalamine; Meta-Analysis as Topic; Middle Aged; Prednisone; Pregnancy; Randomized Controlled Trials as Topic; Risk Factors

2009
Oral budesonide for induction of remission in ulcerative colitis.
    The Cochrane database of systematic reviews, 2010, Oct-06, Issue:10

    Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Randomized Controlled Trials as Topic; Remission Induction

2010
Aminosalicylates for induction of remission or response in Crohn's disease.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Mesalamine; Randomized Controlled Trials as Topic; Remission Induction; Sulfasalazine

2010
Update on the management of Crohn's disease.
    Current gastroenterology reports, 2011, Volume: 13, Issue:5

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Budesonide; Crohn Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Mesalamine; Methotrexate; Natalizumab; Sulfasalazine; Tumor Necrosis Factor-alpha

2011
Risk of postoperative recurrence and postoperative management of Crohn's disease.
    World journal of gastroenterology, 2011, Jul-21, Volume: 17, Issue:27

    Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Crohn Disease; Endoscopy; Gastroenterology; Humans; Inflammation; Mesalamine; Postoperative Period; Recurrence; Risk; Risk Factors; Treatment Outcome

2011
Diarrhea in chronic inflammatory bowel diseases.
    Gastroenterology clinics of North America, 2012, Volume: 41, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals; Bacterial Infections; Biopsy; Bismuth; Blood Cell Count; Blood Chemical Analysis; Body Water; Breath Tests; Budesonide; Cholestyramine Resin; Colitis, Microscopic; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Endoscopy, Gastrointestinal; Feces; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Intestinal Absorption; Intestinal Fistula; Intestinal Mucosa; Intestines; Ion Transport; Malabsorption Syndromes; Medical History Taking; Mesalamine; Organometallic Compounds; Physical Examination; Postoperative Complications; Prednisolone; Salicylates; Sodium; Tumor Necrosis Factor-alpha

2012
Topical therapies in inflammatory bowel disease.
    Digestion, 2012, Volume: 86 Suppl 1

    Topics: Administration, Rectal; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Drug Therapy, Combination; Enema; Guideline Adherence; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Mesalamine; Patient Compliance; Practice Guidelines as Topic; Suppositories

2012
Topical therapy.
    Digestive diseases (Basel, Switzerland), 2012, Volume: 30 Suppl 3

    Topics: Administration, Topical; Adrenal Cortex Hormones; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Rectum

2012
Recent developments in the treatment of inflammatory bowel disease.
    Journal of digestive diseases, 2013, Volume: 14, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Budesonide; Certolizumab Pegol; Evidence-Based Practice; Humans; Immunoglobulin Fab Fragments; Inflammatory Bowel Diseases; Mesalamine; Polyethylene Glycols; Rifamycins; Rifaximin; Ustekinumab

2013
[Prevention of post-operative recurrence in Crohn's disease: a critical review of randomized controlled trials and meta-analyses of different therapeutic strategies].
    Recenti progressi in medicina, 2013, Volume: 104, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Budesonide; Combined Modality Therapy; Crohn Disease; Drug Therapy, Combination; Endoscopy, Digestive System; Humans; Immunosuppressive Agents; Infliximab; Interleukin-10; Lactobacillus; Mesalamine; Meta-Analysis as Topic; Multicenter Studies as Topic; Probiotics; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome

2013
Steroid use in Crohn's disease.
    Drugs, 2014, Volume: 74, Issue:3

    Topics: Adrenal Cortex Hormones; Azathioprine; Budesonide; Clinical Trials as Topic; Crohn Disease; Humans; Mercaptopurine; Mesalamine; Tumor Necrosis Factor-alpha

2014
Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:10

    Topics: Algorithms; Anti-Inflammatory Agents; Budesonide; Chemistry, Pharmaceutical; Colitis, Ulcerative; Delayed-Action Preparations; Glucocorticoids; Humans; Mesalamine; Severity of Illness Index

2014
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:11

    Topics: Adult; Bayes Theorem; Budesonide; Crohn Disease; Humans; Mesalamine; Odds Ratio; Randomized Controlled Trials as Topic

2015
Budesonide for induction of remission in Crohn's disease.
    The Cochrane database of systematic reviews, 2015, Jun-03, Issue:6

    Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Induction Chemotherapy; Mesalamine; Randomized Controlled Trials as Topic

2015
Contemporary methods for the diagnosis and treatment of microscopic colitis.
    Expert review of gastroenterology & hepatology, 2016, Volume: 10, Issue:1

    Topics: Anti-Inflammatory Agents; Antidiarrheals; Bismuth; Budesonide; Colitis, Microscopic; Humans; Immunosuppressive Agents; Induction Chemotherapy; Maintenance Chemotherapy; Mesalamine; Organometallic Compounds; Probiotics; Risk Factors; Salicylates; Tumor Necrosis Factor-alpha

2016
Oral budesonide for induction of remission in ulcerative colitis.
    The Cochrane database of systematic reviews, 2015, Oct-26, Issue:10

    Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Induction Chemotherapy; Mesalamine; Prednisone; Randomized Controlled Trials as Topic

2015
New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
    Inflammatory bowel diseases, 2015, Volume: 21, Issue:12

    Topics: Anti-Inflammatory Agents; Azathioprine; Budesonide; Colitis, Ulcerative; Congresses as Topic; Crohn Disease; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Maintenance Chemotherapy; Mesalamine; Methotrexate; Review Literature as Topic; Secondary Prevention

2015
Budesonide for the treatment of ulcerative colitis.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:11

    Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents; Biological Availability; Budesonide; Chemistry, Pharmaceutical; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction; Steroids; Treatment Outcome

2016
Aminosalicylates for induction of remission or response in Crohn's disease.
    The Cochrane database of systematic reviews, 2016, Jul-03, Volume: 7

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Delayed-Action Preparations; Gastrointestinal Agents; Humans; Induction Chemotherapy; Mesalamine; Randomized Controlled Trials as Topic; Sulfasalazine

2016
The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:1

    Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Medication Adherence; Mesalamine; Polymers; Remission Induction; Treatment Outcome

2017
Diagnosis and Management of Microscopic Colitis.
    The American journal of gastroenterology, 2017, Volume: 112, Issue:1

    Topics: Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals; Autoimmunity; Bile Acids and Salts; Budesonide; Cholestyramine Resin; Colitis, Collagenous; Colitis, Lymphocytic; Colitis, Microscopic; Collagen; Colon; Genetic Predisposition to Disease; Glucocorticoids; HLA Antigens; Humans; Mesalamine

2017
[Second Korean Guidelines for the Management of Crohn's Disease].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2017, Jan-25, Volume: 69, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Infliximab; Mercaptopurine; Mesalamine; Methotrexate; Prednisolone; Severity of Illness Index; Tumor Necrosis Factor-alpha

2017
Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Inflammatory bowel diseases, 2017, Volume: 23, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Bayes Theorem; Budesonide; Comparative Effectiveness Research; Crohn Disease; Humans; Induction Chemotherapy; Mesalamine; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Sulfasalazine; Treatment Outcome

2017
Interventions for treating lymphocytic colitis.
    The Cochrane database of systematic reviews, 2017, 07-13, Volume: 7

    Topics: Anti-Inflammatory Agents; Antidiarrheals; Beclomethasone; Bismuth; Budesonide; Cholestyramine Resin; Colitis, Lymphocytic; Humans; Mesalamine; Organometallic Compounds; Randomized Controlled Trials as Topic; Salicylates

2017
Interventions for treating collagenous colitis.
    The Cochrane database of systematic reviews, 2017, 11-11, Volume: 11

    Topics: Bismuth; Boswellia; Budesonide; Cholestyramine Resin; Chronic Disease; Colitis, Collagenous; Diarrhea; Glucocorticoids; Humans; Mesalamine; Organometallic Compounds; Plant Extracts; Prednisolone; Probiotics; Randomized Controlled Trials as Topic; Salicylates

2017
A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
    Expert opinion on drug safety, 2018, Volume: 17, Issue:4

    Topics: Administration, Oral; Anti-Inflammatory Agents; Biological Availability; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Drug Delivery Systems; Humans; Mesalamine; Severity of Illness Index

2018
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:11

    Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Network Meta-Analysis; Remission Induction; Sulfasalazine

2018
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:10

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Glucocorticoids; Humans; Mesalamine; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome

2019
Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients.
    Revista espanola de enfermedades digestivas, 2020, Volume: 112, Issue:1

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antidiarrheals; Antimetabolites; Azathioprine; Biological Products; Budesonide; Colitis, Collagenous; Colitis, Lymphocytic; Colitis, Microscopic; Diarrhea; Humans; Loperamide; Malabsorption Syndromes; Mesalamine; Methotrexate; Prednisolone; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Time Factors

2020
Crohn's Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review.
    Cancer research and treatment, 2020, Volume: 52, Issue:4

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Immunological; Budesonide; Carcinoma, Signet Ring Cell; Crohn Disease; Drug Therapy, Combination; Humans; Induction Chemotherapy; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Mesalamine; Middle Aged; Neoplasms, Multiple Primary; Rituximab; Stomach Neoplasms; Treatment Outcome

2020
Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.
    AAPS PharmSciTech, 2021, Nov-03, Volume: 22, Issue:8

    Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Retrospective Studies; Technology

2021
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review.
    United European gastroenterology journal, 2022, Volume: 10, Issue:8

    Topics: Budesonide; Colitis, Ulcerative; Humans; Mesalamine

2022
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
    Alimentary pharmacology & therapeutics, 2023, Volume: 58, Issue:8

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Proctitis; Remission Induction; Tacrolimus

2023

Trials

17 trial(s) available for mesalamine and pulmicort

ArticleYear
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    The New England journal of medicine, 1998, Aug-06, Volume: 339, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Hydrocortisone; Male; Mesalamine; Middle Aged; Remission Induction

1998
Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
    Gut, 1999, Volume: 45, Issue:1

    Topics: Administration, Topical; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Glucocorticoids; Humans; Mesalamine; Randomized Controlled Trials as Topic

1999
[Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:4

    Topics: Administration, Rectal; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Middle Aged; Pilot Projects; Proctoscopy; Prospective Studies; Treatment Outcome

2000
Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Double-Blind Method; Female; Health Status; Humans; Male; Mesalamine; Middle Aged; Quality of Life; Severity of Illness Index

2002
Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2003, Volume: 1, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Female; Humans; Male; Mesalamine; Middle Aged; Prospective Studies; Quality of Life; Remission Induction; Single-Blind Method; Treatment Outcome

2003
Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
    Alimentary pharmacology & therapeutics, 2010, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Middle Aged; Quality of Life; Treatment Outcome; Young Adult

2010
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Gastroenterology, 2011, Volume: 140, Issue:2

    Topics: Adult; Anti-Inflammatory Agents; Budesonide; Crohn Disease; Double-Blind Method; Female; Humans; Male; Mesalamine; Middle Aged; Remission Induction; Severity of Illness Index; Smoking; Treatment Outcome; Young Adult

2011
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
    Journal of Crohn's & colitis, 2011, Volume: 5, Issue:2

    Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Chi-Square Distribution; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Hydrocortisone; Kaplan-Meier Estimate; Male; Mesalamine; Middle Aged; Remission Induction

2011
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Gastroenterology, 2012, Volume: 143, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Mesalamine; Middle Aged; Remission Induction; Treatment Outcome; Young Adult

2012
Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
    Gastroenterology, 2014, Volume: 146, Issue:5

    Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Capsules; Colitis, Collagenous; Defecation; Delayed-Action Preparations; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Remission Induction; Time Factors; Treatment Outcome; Young Adult

2014
Smoking Status Influences Clinical Outcome in Collagenous Colitis.
    Journal of Crohn's & colitis, 2016, Volume: 10, Issue:4

    Topics: Aged; Budesonide; Colitis, Collagenous; Colon; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Prognosis; Remission Induction; Smoking; Treatment Outcome

2016
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Inflammatory bowel diseases, 2016, Volume: 22, Issue:8

    Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Colon, Sigmoid; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Mesalamine; Middle Aged; Proctitis; Proctocolitis; Remission Induction; Severity of Illness Index

2016
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Journal of Crohn's & colitis, 2017, Jul-01, Volume: 11, Issue:7

    Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Colonoscopy; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Hydrocortisone; Intention to Treat Analysis; Male; Mesalamine; Middle Aged; Remission Induction; Retreatment; Severity of Illness Index

2017
Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Male; Mesalamine; Middle Aged; Proctitis; Prospective Studies; Russia; Suppositories; Treatment Outcome; Young Adult

2019
Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
    Gastroenterology, 2018, Volume: 155, Issue:6

    Topics: Administration, Oral; Anti-Inflammatory Agents; Budesonide; Colitis, Lymphocytic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Male; Mesalamine; Middle Aged; Treatment Outcome

2018
Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    United European gastroenterology journal, 2020, Volume: 8, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Colon; Colonoscopy; Delayed-Action Preparations; Drug Administration Schedule; Drug Resistance; Female; Humans; Intestinal Mucosa; Male; Mesalamine; Middle Aged; Proof of Concept Study; Remission Induction; Treatment Outcome; Young Adult

2020
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
    Journal of Crohn's & colitis, 2022, Nov-23, Volume: 16, Issue:11

    Topics: Budesonide; Colitis, Ulcerative; Double-Blind Method; Humans; Mesalamine; Proctitis; Quality of Life; Remission Induction; Treatment Outcome

2022

Other Studies

57 other study(ies) available for mesalamine and pulmicort

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid.
    Scandinavian journal of gastroenterology, 1998, Volume: 33, Issue:2

    Topics: Animals; Budesonide; Colitis; Colon; Cyclosporine; Disease Models, Animal; Female; Intestinal Mucosa; Mesalamine; Organ Size; Oxazolone; Peroxidase; Rats; Time Factors

1998
Treatment of Crohn's disease at the turn of the century.
    The New England journal of medicine, 1998, Aug-06, Volume: 339, Issue:6

    Topics: Administration, Topical; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Budesonide; Crohn Disease; Glucocorticoids; Humans; Mesalamine; Tumor Necrosis Factor-alpha

1998
A comparison of budesonide and mesalamine for active Crohn's disease.
    Gastroenterology, 1999, Volume: 116, Issue:5

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Immunosuppressive Agents; Mesalamine; Multicenter Studies as Topic; Prednisolone; Remission Induction

1999
[Extra-intestinal manifestations and complications in chronic active ulcerative colitis in childhood and adolescence].
    Deutsche medizinische Wochenschrift (1946), 1999, Jul-09, Volume: 124, Issue:27

    Topics: Adolescent; Azathioprine; Budesonide; Child; Colitis, Ulcerative; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Leg Ulcer; Male; Mesalamine; Prednisolone; Pyoderma Gangrenosum; Treatment Outcome

1999
Beneficial effects of ropivacaine in rat experimental colitis.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:2

    Topics: Acetylcholine; Amides; Anesthetics, Local; Animals; Budesonide; Colitis; Ethanol; Gastrointestinal Motility; In Vitro Techniques; Male; Mesalamine; Mucous Membrane; Peroxidase; Rats; Rats, Sprague-Dawley; Ropivacaine; Time Factors; Trinitrobenzenesulfonic Acid; Wound Healing

1999
Drug Points: Anaphylactic-like reaction associated with oral budesonide.
    BMJ (Clinical research ed.), 2000, Oct-14, Volume: 321, Issue:7266

    Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Mesalamine

2000
[Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital].
    Medizinische Klinik (Munich, Germany : 1983), 2002, Mar-15, Volume: 97, Issue:3

    Topics: Adult; Ambulatory Care; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Cost of Illness; Costs and Cost Analysis; Crohn Disease; Drug Costs; Germany; Health Care Costs; Health Resources; Hospitals, University; Humans; Mesalamine

2002
Ileal Crohn's disease is best treated by surgery.
    Gut, 2002, Volume: 51, Issue:1

    Topics: Azathioprine; Budesonide; Crohn Disease; Glucocorticoids; Humans; Ileum; Mesalamine; Prednisolone

2002
[Treatment of steroid-refractory ulcerative colitis with infliximab].
    Gastroenterologia y hepatologia, 2003, Volume: 26, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Blood Transfusion; Budesonide; Colitis, Ulcerative; Drug Resistance; Drug Therapy, Combination; Enteral Nutrition; Female; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methylprednisolone; Prednisone; Remission Induction; Tumor Necrosis Factor-alpha

2003
[Acute episode].
    Zeitschrift fur Gastroenterologie, 2003, Volume: 41, Issue:1

    Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Child; Controlled Clinical Trials as Topic; Crohn Disease; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Mercaptopurine; Mesalamine; Meta-Analysis as Topic; Nutritional Physiological Phenomena; Prednisolone; Time Factors

2003
[Maintaining a remission].
    Zeitschrift fur Gastroenterologie, 2003, Volume: 41, Issue:1

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Child; Crohn Disease; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Male; Mercaptopurine; Mesalamine; Meta-Analysis as Topic; Methotrexate; Placebos; Postoperative Care; Prednisolone; Pregnancy; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Time Factors

2003
Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:2

    Topics: Aged; Budesonide; Cholestyramine Resin; Colitis; Collagen; Colon; Female; Follow-Up Studies; Humans; Lymphocytosis; Male; Mesalamine; Middle Aged; Prednisone; Prospective Studies; Time Factors

2003
[New research results give hope. Causal therapy of Crohn disease in sight].
    MMW Fortschritte der Medizin, 2004, Apr-01, Volume: 146, Issue:14

    Topics: Algorithms; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Crohn Disease; Defensins; Humans; Immunosuppressive Agents; Mesalamine; Prednisolone; Prognosis; Time Factors; Trichuris

2004
[Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17

    Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesalamine; Quality of Life; Sulfasalazine; Time Factors

2005
Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.
    The Journal of pharmacy and pharmacology, 2005, Volume: 57, Issue:6

    Topics: Anti-Inflammatory Agents; Budesonide; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Delivery Systems; Gastrointestinal Transit; Hydrogen-Ion Concentration; Kinetics; Mesalamine; Models, Biological; Solubility; Spectrophotometry, Ultraviolet

2005
[Paradigmatic shift in drug treatment of Crohn disease].
    Ugeskrift for laeger, 2005, Aug-15, Volume: 167, Issue:33

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Immunosuppressive Agents; Mesalamine; Prednisolone; Secondary Prevention

2005
[Crohn disease, exacerbated during pregnancy].
    Deutsche medizinische Wochenschrift (1946), 2007, Apr-20, Volume: 132, Issue:16

    Topics: Adult; Anti-Inflammatory Agents; Budesonide; Crohn Disease; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Intestine, Small; Mesalamine; Pregnancy; Pregnancy Complications; Ultrasonography

2007
Microscopic colitis: not just for aristocrats.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:6

    Topics: Budesonide; Cholestyramine Resin; Colitis, Microscopic; Humans; Immunosuppressive Agents; Incidence; Mesalamine; Risk Factors

2007
[Patients prefer foam].
    MMW Fortschritte der Medizin, 2007, May-24, Volume: 149, Issue:21

    Topics: Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Dosage Forms; Drug Therapy, Combination; Humans; Mesalamine; Patient Acceptance of Health Care; Treatment Outcome

2007
[Collagenous colitis. Clinicopathological study of 18 cases].
    Revista clinica espanola, 2007, Volume: 207, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Budesonide; Colitis, Collagenous; Colon; Colonoscopy; Diarrhea; Female; Glucocorticoids; Humans; Male; Mesalamine; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome

2007
Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile?
    Inflammatory bowel diseases, 2008, Volume: 14, Issue:2

    Topics: Adult; Aged; Azathioprine; Budesonide; Canada; Crohn Disease; Cross-Sectional Studies; Decision Support Techniques; Fees, Pharmaceutical; Female; Fish Oils; Focus Groups; Gastrointestinal Agents; Humans; Male; Mesalamine; Metronidazole; Middle Aged; Patient Satisfaction; Postoperative Care; Regression Analysis; Reproducibility of Results; Secondary Prevention

2008
[Treating distal ulcerative colitis intrarectally. Foam instead of enema, low volume rather than high volume].
    MMW Fortschritte der Medizin, 2008, Apr-10, Volume: 150, Issue:15

    Topics: Administration, Rectal; Budesonide; Colitis, Ulcerative; Enema; Humans; Hydrocortisone; Mesalamine; Patient Acceptance of Health Care; Proctocolitis; Randomized Controlled Trials as Topic

2008
Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:5

    Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Budesonide; Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Female; Humans; Ileitis; Incidence; Male; Mesalamine; Metronidazole; Middle Aged; Pouchitis; Proctocolectomy, Restorative; Prospective Studies; Retrospective Studies

2009
[Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    MMW Fortschritte der Medizin, 2010, Jan-14, Volume: 152, Issue:1-2

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Mesalamine; Methotrexate; Practice Guidelines as Topic; Prednisolone; Remission Induction

2010
Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
    Journal of drug targeting, 2011, Volume: 19, Issue:2

    Topics: Administration, Oral; Anhydrides; Animals; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Colon; Dextrans; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Glutarates; Hydrogen-Ion Concentration; Male; Mesalamine; Molecular Weight; Rats; Rats, Wistar

2011
Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
    American journal of hematology, 2010, Volume: 85, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Chromosomes, Human, Pair 7; Combined Modality Therapy; Crohn Disease; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Monocytic, Acute; Male; Mercaptopurine; Mesalamine; Methyltransferases; Monosomy; Myelodysplastic Syndromes; Prednisone; Young Adult

2010
Small intestinal release mesalamine for the treatment of refractory celiac disease type I.
    Journal of clinical gastroenterology, 2011, Volume: 45, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Celiac Disease; Female; Glucocorticoids; Headache; Humans; Intestine, Small; Male; Mesalamine; Middle Aged; Treatment Outcome

2011
Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study.
    Journal of Crohn's & colitis, 2011, Volume: 5, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Budesonide; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Cyclosporine; Female; Germany; Humans; Immunosuppressive Agents; Infliximab; Male; Mercaptopurine; Mesalamine; Methotrexate; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Remission Induction; Severity of Illness Index; Sex Factors; Tacrolimus

2011
Budesonide use in pediatric Crohn disease.
    Journal of pediatric gastroenterology and nutrition, 2012, Volume: 55, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Budesonide; Child; Colon; Colonic Diseases; Crohn Disease; Drug Therapy, Combination; Female; Humans; Ileal Diseases; Ileum; Immunologic Factors; Male; Mesalamine; Prednisone; Young Adult

2012
[Guidelines for the management of Crohn's disease].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2012, Volume: 59, Issue:2

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Budesonide; Crohn Disease; Databases, Factual; Female; Fistula; Humans; Infliximab; Intestinal Perforation; Male; Mercaptopurine; Mesalamine; Methotrexate; Prednisolone; Pregnancy; Recurrence; Risk Factors; Severity of Illness Index; Sulfasalazine

2012
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease.
    Journal of Crohn's & colitis, 2013, Volume: 7, Issue:6

    Topics: Adalimumab; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Azathioprine; Budesonide; Cells, Cultured; Crohn Disease; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Interferon-gamma; Interleukin-10; Male; Mesalamine; Middle Aged; Retrospective Studies; T-Lymphocytes; Tumor Necrosis Factor-alpha; Young Adult

2013
Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
    Life sciences, 2013, Apr-09, Volume: 92, Issue:12

    Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Budesonide; Colitis; Colon; Cyclosporine; Dextran Sulfate; Drug Therapy, Combination; Female; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Mesalamine; Mice; Mice, Inbred BALB C; Receptors, Prostaglandin E, EP4 Subtype; Thioguanine

2013
Topical therapy is underused in patients with ulcerative colitis.
    Journal of Crohn's & colitis, 2014, Volume: 8, Issue:1

    Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Enema; Female; Humans; Immunologic Factors; Male; Mesalamine; Middle Aged; Proctitis; Severity of Illness Index; Switzerland; Tumor Necrosis Factor-alpha; Young Adult

2014
Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins.
    Scandinavian journal of gastroenterology, 2014, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Bacterial; Antibodies, Monoclonal; Azathioprine; Bacterial Proteins; Budesonide; Case-Control Studies; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infliximab; Male; Mesalamine; Middle Aged; Mycobacterium avium subsp. paratuberculosis; Prednisone; Protein Tyrosine Phosphatases; Young Adult

2014
Efficacy of budesonide in collagenous colitis Evaluation of: Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146(5):1222-1230 e1222.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:15

    Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Collagenous; Female; Gastrointestinal Agents; Humans; Male; Mesalamine

2014
[Chronic inflammatory bowel diseases. Strive for healing the mucosa, prevent overtreatment].
    MMW Fortschritte der Medizin, 2014, Jul-24, Volume: 156, Issue:13

    Topics: Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Intestinal Mucosa; Mesalamine; Phosphatidylcholines

2014
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:5

    Topics: Adolescent; Adult; Aged; Budesonide; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Colonoscopy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Socioeconomic Factors; Young Adult

2015
[The first oral budesonide: effective in an acute episode].
    MMW Fortschritte der Medizin, 2015, Jul-23, Volume: 157, Issue:13

    Topics: Acute Disease; Administration, Oral; Administration, Rectal; Budesonide; Colitis, Ulcerative; Drug Approval; Drug Therapy, Combination; Germany; Humans; Medication Adherence; Mesalamine

2015
[Not a cure, but a normal life].
    MMW Fortschritte der Medizin, 2016, Feb-04, Volume: 158, Issue:2

    Topics: Azathioprine; Biological Products; Budesonide; Cell Adhesion Molecules; Drug Therapy, Combination; Humans; Inflammatory Bowel Diseases; Mesalamine; Tumor Necrosis Factor-alpha

2016
Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2016, Volume: 103

    Topics: Budesonide; Delayed-Action Preparations; Humans; Inflammatory Bowel Diseases; Mesalamine; Tablets

2016
Collagenous colitis and Crohn's disease: Guilty or innocent bystander?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:10

    Topics: Aged; Budesonide; Colitis, Collagenous; Colon; Colonoscopy; Crohn Disease; Humans; Male; Mesalamine; Recurrence

2016
Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
    Journal of Crohn's & colitis, 2017, Jul-01, Volume: 11, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Drug Delivery Systems; Drug Therapy, Combination; Glucocorticoids; Humans; Mesalamine; Risk Assessment

2017
Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?
    Inflammatory bowel diseases, 2017, Volume: 23, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Mesalamine; Remission Induction

2017
Rosacea fulminans - coincidence of the disease with inflammatory bowel disease.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:6

    Topics: Anti-Inflammatory Agents; Budesonide; Dermatologic Agents; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Middle Aged; Rosacea

2019
ACG Clinical Guideline: Ulcerative Colitis in Adults.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:3

    Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Budesonide; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplasms; Disease Management; Early Detection of Cancer; Gastroenterology; Gastrointestinal Agents; Humans; Infliximab; Maintenance Chemotherapy; Mesalamine; Prognosis; Remission Induction; Severity of Illness Index; Societies, Medical; Tumor Necrosis Factor-alpha

2019
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:9

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Azathioprine; Budesonide; Canada; Crohn Disease; Gastroenterology; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Induction Chemotherapy; Maintenance Chemotherapy; Mesalamine; Methotrexate; Prednisolone; Societies, Medical; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab

2019
Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2019, Apr-25, Volume: 73, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Colonoscopy; Female; Humans; Mesalamine; Methylprednisolone; Pneumonia; Probiotics; Pulmonary Eosinophilia; Recurrence; Thorax; Tomography, X-Ray Computed

2019
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
    United European gastroenterology journal, 2019, Volume: 7, Issue:9

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Colitis, Ulcerative; Dosage Forms; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Italy; Logistic Models; Male; Mesalamine; Middle Aged; Multivariate Analysis; Retrospective Studies; Severity of Illness Index; Sulfasalazine; Treatment Outcome

2019
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®
    United European gastroenterology journal, 2019, Volume: 7, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Cohort Studies; Colitis, Ulcerative; Dosage Forms; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Mesalamine; Middle Aged; Prospective Studies; Severity of Illness Index; Treatment Outcome

2019
Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease.
    Journal of gastrointestinal and liver diseases : JGLD, 2019, Dec-19, Volume: 28, Issue:suppl. 4

    Topics: Aged; Budesonide; Colonic Diseases; Diverticular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Feces; Female; Follow-Up Studies; Gastrointestinal Agents; Glucocorticoids; Humans; Leukocyte L1 Antigen Complex; Male; Mesalamine; Middle Aged; Severity of Illness Index; Treatment Outcome

2019
A new kid on the budesonide block.
    United European gastroenterology journal, 2020, Volume: 8, Issue:10

    Topics: Budesonide; Colitis, Ulcerative; Humans; Mesalamine

2020
Panuveitis in a patient with active Crohn's disease.
    BMJ case reports, 2021, Feb-04, Volume: 14, Issue:2

    Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colonoscopy; Crohn Disease; Female; Humans; Mesalamine; Panuveitis; Tomography, Optical Coherence

2021
Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study.
    BMC gastroenterology, 2022, Jun-24, Volume: 22, Issue:1

    Topics: Budesonide; Colitis, Ulcerative; Defecation; Humans; Mesalamine; Quality of Life; Treatment Outcome

2022